# US 2022/0009989 A1 · Bifunctional compounds comprising insulin peptides and egf(a) peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009989 A1
- Document ID: US20220009989A1
- Status: Published application
- Kind: A1
- Application number: 17/281,813
- Filed: 2019-10-04
- Published: 2022-01-13
- Earliest claimed: 2018-10-05
- Assignees: Novo Nordisk A/S
- Applicants: Novo Nordisk A/S
- Inventors: Martin Werner Borchsenius Muenzel; Susanne Hostrup; Gro Klitgaard Povlsen; Mathias Norrman; Thomas Boerglum Kjeldsen; Claudia Ulrich Hjoerringgaard; Peter Madsen
- Web page: https://patentgrep.com/patent/US20220009989A1

## CPC

- C07K 14/62: Insulins
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 9/6454: {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.

## Claims

### Claim 1

A fusion protein comprising:
an insulin peptide, an Epidermal Growth Factor-like domain (A) (EGF(A)) peptide, a spacer and a substituent, wherein:
i. said insulin peptide is human insulin (SEQ ID NOs 2 and 3) or an analogue of human insulin,
ii. said EGF(A) peptide is an analogue of the EGF(A) domain of LDL-R (293-332) according to SEQ ID NO:1,
iii. said spacer is a peptide linker comprising segments of (GAQP)n or (GQAP)n, wherein n=1-20, and connecting the N-terminal of the insulin analogue B-chain with the C-terminal of the EGF(A) analogue and
iv. said substituent is of formula (I): Acy-AA2m-AA3p-, wherein
Acy is a fatty diacid comprising from about 16 to about 20 carbon atoms,
AA2 is an acidic amino acid residue and wherein m is an integer in the range from 1 to 10, and
AA3 is a neutral, alkyleneglycol-containing amino acid residue and p is an integer in the range from 1 to 10, and
wherein the maximum number of AA2 and AA3 residues is 10, and
wherein the AA2 and AA3 residues may appear in any order,
or a pharmaceutically acceptable salt, amide, or ester thereof.

### Claim 2 (depends on 1)

The fusion protein according to claim 1, wherein said EGF(A) analogue comprises 301L.

### Claim 3 (depends on 2)

The fusion protein according to claim 2, wherein said EGF(A) analogue further comprises 309R; [309R, 312E] or [309R, 312E, 321E].

### Claim 4 (depends on 1)

The fusion protein according to claim 1, wherein said EGF(A) analogue sequence is 301L, 309R, 312E and 321E.

### Claim 5 (depends on 1)

The fusion protein according to claim 1, wherein the insulin peptide is human insulin or an analogue/derivative of human insulin comprising up to 12 mutations.

### Claim 6 (depends on 1)

The fusion protein according to claim 1, wherein said insulin analogue comprises desB30.

### Claim 7 (depends on 1)

The fusion protein according to claim 1, wherein said spacer comprises (GAQP)n, wherein n is 2-10.

### Claim 8 (depends on 1)

The fusion protein according to claim 1, wherein said substituent is attached via a Lys/K amino acid residue in the insulin sequence within said compound.

### Claim 9 (depends on 8)

The fusion protein according to claim 8, wherein said substituent attached via a Lys/K amino acid residue B29K in the insulin sequence of said compound.

### Claim 10 (depends on 9)

The fusion protein according to claim 9, wherein the at least one acyl moiety comprises a fatty diacid group selected from 1,16-hexadecanedioic acid; 1,18-octadecanedioic acid and 1,20-eicosanedioic acid.

### Claim 11 (depends on 1)

The fusion protein according to claim 1, wherein said fusion protein is selected from the group consisting of compounds of examples 1-24 (SEQ ID Nos 17-40):
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B3E, B29K(hexadecanedioyl-gGlu-2×OEG), desB30) (Chem. 1)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]10-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 2)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B3E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 3)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 4)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B3E, B29K(octadecanedioyl-gGlu-OEG), desB30) (Chem. 5)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B3E, B29K(eicosanedioyl-gGlu-2×OEG), desB30) (Chem. 6)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]2-Insulin(B29K(eicosanedioyl-gGlu-2×OEG), desB30) (Chem. 7)
EGF(A)(301L, 309R, 312E, 321E)-[GQAP]2-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 8)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]3-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 9)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]3-Insulin(A14E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 10)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]4-Insulin(A14E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 11)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]4-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 12)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]6-Insulin(A14E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 13)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]6-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 14)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]6-Insulin(A14E, B29K(octadecanedioyl-gGlu-OEG), desB30) (Chem. 15)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]6-Insulin(A14E, B29K(eicosanedioyl-gGlu-2×OEG), desB30 (Chem. 16)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]8-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 17)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]12-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 18)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 19)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(A14E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 20)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(B3E, B29K(octadecanedioyl-gGlu-2×OEG), desB30) (Chem. 21)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(B29K(eicosanedioyl-gGlu-2×OEG), desB30) (Chem. 22)
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(A14E, B29K(eicosanedioyl-gGlu-2×OEG), desB30) (Chem. 23) and
EGF(A)(301L, 309R, 312E, 321E)-[GAQP]19-Insulin(B3E, B29K(eicosanedioyl-gGlu-2×OEG), desB30) (Chem. 24)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a fusion protein according to claim 1, together with a pharmaceutically acceptable excipient.

### Claim 15 (depends on 14)

A method comprising: administering to a subject in need of treatment or prevention of diabetes, diabetes of Type 1, diabetes of Type 2, impaired glucose tolerance, hyperglycemia and diabetic dyslipidemia a pharmaceutically effective amount of the composition of claim 14.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the subject is in need of treatment or prevention of diabetes and dyslipidaemia associated with diabetes
